Aktis Oncology, Inc.
Clinical trials sponsored by Aktis Oncology, Inc., explained in plain language.
A clinical-stage biotech developing targeted radiopharmaceuticals for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC